Is Combined Bulevirtide and Pegylated Interferon Therapy for Chronic Hepatitis D Superior over Bulevirtide Monotherapy?

• Main Authors: V. E. Syutkin, A. O. Bueverov, P. O. Bogomolov
• Format: Article
• Language: Russian
• Published: Gastro LLC 2020-09-01
• Series: Российский журнал гастроэнтерологии, гепатологии, колопроктологии
• Subjects: hepatitis d virus; chronic hepatitis d; bulevirtide; pegylated interferon
• Online Access: https://www.gastro-j.ru/jour/article/view/489

Bulevirtide is a novel antiviral agent approved for suppression of chronic hepatitis D but requiring further research into optimising the treatment scheme.Aim. Comparative assessment of bulevirtide monotherapy versus combined treatment with bulevirtide and pegylat-ed interferon (PEG-IFN) using published trial data.Key points. MYR201 and MYR203 trials expose a higher frequency of HBsAg and HDV RNA extinction, as well as more effective HDV suppression for combined bulevirtide/PEG-IFN therapy compared to bulevirtide monotherapy.Conclusion. Combined bulevirtide/PEG-IFN therapy has particular advantages over bulevirtide monotherapy in patients with chronic hepatitis D. Further research is required to optimise bulevirtide dosage and duration of therapy.